Bristol-Myers Squibb Company (BMY)
Bristol Myers plans to launch schizophrenia drug in UK at list price equal to the US
Bristol Myers Squibb said on Monday that it plans to launch its schizophrenia treatment Cobenfy in the UK in 2026 at a price that is equal to its US list price.
Bristol Myers Squibb: Buy This Deep Bargain Before The Market Wakes To Income
Bristol Myers Squibb is a deep value opportunity, trading at a forward PE of 7x and offering a 5.5% dividend yield. BMY's next-gen portfolio drives double-digit growth, with blockbuster drugs like Reblozyl and Camzyos offsetting legacy declines. Strategic partnerships, a robust pipeline, and expanding opportunities in oncology and Alzheimer's position BMY for long-term relevance.
Bristol Myers to sell 60% stake in China joint venture
U.S. drugmaker Bristol Myers Squibb said on Tuesday it has signed an agreement to sell its 60% ownership stake in a pharmaceutical joint venture in China.
Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?
Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.
BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial
A next-generation cancer immunotherapy by BioNTech and partner Bristol Myers Squibb led to encouraging tumour shrinkage in a mid-stage trial on small cell lung cancer that has started spreading, the German biotech firm said on Monday.
Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership
Bristol-Myers Squibb is a Strong Buy at current levels, with a $54 price target and attractive 5.2% dividend yield. The company's innovative growth portfolio is gaining traction, offsetting legacy declines and positioning BMY for a turnaround. Valuation is compelling: BMY trades at a deep discount to peers, with limited downside and strong profitability metrics.
7 Big Yields From The Beat-Up Healthcare Sector
Healthcare stocks haven't moved since the April lows. As contrarian investors, this neglect piques our interest.
BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now?
Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.
5 Strong-Buy Stocks With Hard-to-Find 5% and Higher Yields
Dividend stocks are a favorite among investors for good reason. They provide a steady income stream and offer a promising avenue for total return.
Does Cobenfy Have the Potential to Become a Top Drug for BMY?
Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?
Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.
